Skip to main content
MEDIPOSTCO.,LTD. logo

MEDIPOSTCO.,LTD. — Investor Relations & Filings

Ticker · 078160 ISIN · KR7078160009 KO Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country KR South Korea
Listing KO 078160

About MEDIPOSTCO.,LTD.

https://en.medi-post.co.kr/

MEDIPOST is a biotechnology company specializing in the research, development, and commercialization of stem cell therapeutics and regenerative medicine. The company focuses on addressing unmet medical needs for incurable diseases through its proprietary stem cell platform technology. Its core operations include a cord blood banking service and the development of allogeneic stem cell therapies. Key commercialized products include CARTISTEM®, a treatment for knee cartilage defects and osteoarthritis, and PNEUMOSTEM®, a preventive therapy for bronchopulmonary dysplasia in premature infants. The company's clinical pipeline features next-generation injectable treatments for conditions such as osteoarthritis and diabetic nephropathy.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정
Regulatory Filings Classification · 60% confidence The document is a statutory announcement in Korean regarding the decision to acquire equity securities of another company (“타법인 주식 및 출자증권 취득결정”). It is not issuing new shares, a buyback of its own shares, nor an interim or annual financial report, dividend notice, management change, or AGM material. It does not fit the specific M&A takeover or tender‐offer forms covered under TAR/MA, nor financing updates (CAP). It is a routine regulatory disclosure of a corporate action (investment), so it falls into the miscellaneous regulatory filing category.
2026-06-04 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제27기 1분기)” covering the period 2026-01-01 to 2026-03-31, submitted to the Financial Supervisory Service and Korea Exchange. It contains detailed corporate information, financial data, stock and capital changes, governance, subsidiary details, and other substantive interim financial statements. This matches the definition of an Interim/Quarterly Report rather than an announcement or summary. Therefore, the appropriate classification is IR (Interim / Quarterly Report). Q1 2026
2026-05-15 Korean
기업설명회(IR)개최
Investor Presentation Classification · 90% confidence The document is a corporate notice in Korean announcing the scheduling and details of a one-on-one investor relations presentation (IR event) including dates, times, venue, attendees, agenda and posting information on the company website and KRX KIND. This clearly matches the definition of an Investor Presentation (Code: IP).
2026-04-24 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is the official results of a regular shareholders’ meeting (정기주주총회결과) held on 2026-03-27. It lists voting items (approval of financial statements, auditor’s report, director appointment, articles amendment), vote counts, percentages, and whether each resolution passed. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-27 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing by MediPost regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and the company's compliance status with the KOSDAQ Association's guidelines. Since this is a specific regulatory disclosure regarding meeting logistics rather than the meeting materials themselves (AGM-R) or a proxy statement (PSI), it falls under the general regulatory filing category.
2026-03-20 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Medipost Co., Ltd. for the fiscal year ending December 31, 2025. It includes the independent auditor's opinion from Hanwool Accounting Corporation, key audit matters, and the full set of financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes. This is a comprehensive audit document, not an earnings release or a simple announcement. FY 2025
2026-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.